Allogeneic CD4+ T-Cell Infusion for Reversing Tumor T-Cell Exhaustion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer immunotherapy faces limitations due to T cell exhaustion, where tumor-specific CD4+ T cells become functionally paralyzed, preventing effective CD8+ T cell-mediated cancer elimination, despite the success of immunologic checkpoint inhibitors.
Innovation Solution
Infusion of allogeneic lymphocytes containing CD4+ T cells, depleted of CD8+ T cells and optionally regulatory T cells, to provide exogenous help for endogenous tumor-reactive CD8+ T cells, augmented by chemotherapy and antigen-specific expansion, leveraging HLA-matched or haploidentical donors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunologic checkpoint inhibitors are used to treat cancer, then tumor regression and prolonged survival are achieved, but T cell exhaustion limits the effectiveness of the therapy
Solution Approach 1:
The patent applies preliminary action by vaccinating the donor against tumor-specific antigens before harvesting lymphocytes. This pre-vaccination ensures that the donor's CD4+ T cells are already activated and expanded against the target antigen, so when these cells are infused into the recipient, they immediately provide helper function to activate the recipient's tumor-specific CD8+ T cells, overcoming the exhaustion problem before it can develop
Solution Approach 2:
The patent uses allogeneic CD4+ T cells as an intermediary mediator between the vaccine antigen and the recipient's tumor-specific CD8+ T cells. The infused CD4+ T cells recognize tumor antigens presented by antigen-presenting cells, become activated, and then provide cytokine help (particularly IL-2) and co-stimulation to reactivate exhausted tumor-specific CD8+ T cells, thereby mediating the restoration of anti-tumor immunity
2Reliability
If allogeneic lymphocytes are infused to provide CD4+ helper T cells, then anti-tumor immunity is enhanced, but graft-versus-host disease risk increases
Solution Approach 1:
The patent applies the taking out principle by selectively removing CD8+ T cells from the donor lymphocyte infusion. Since CD8+ T cells are the primary mediators of graft-versus-host disease (GVHD) while CD4+ T cells provide the desired helper function for anti-tumor immunity, depleting CD8+ T cells from the infused population eliminates the harmful GVHD effect while preserving the beneficial CD4+ T cell-mediated immune enhancement
Solution Approach 2:
The patent applies segmentation by separating the donor lymphocyte population into distinct CD4+ T cell and CD8+ T cell fractions, then selectively infusing only the CD4+ T cell fraction. This segmentation allows the therapy to deliver the specific helper T cell function needed to reverse T cell exhaustion while excluding the cytotoxic CD8+ T cells that would cause harmful GVHD in the recipient
3Reliability
If tumor-specific CD4+ T cells are depleted to reverse exhaustion, then CD8+ T cell-mediated cancer elimination is improved, but the source of helper T cell function is reduced
Solution Approach 1:
The patent applies the copying principle by creating ex vivo expanded copies of tumor-specific CD4+ T cells from a vaccinated donor. Instead of relying on the recipient's own depleted CD4+ T cells, the therapy harvests lymphocytes from a donor who has been immunized against the tumor antigen, expands the CD4+ T cell population in culture, and infuses these copied helper T cells into the recipient, thereby replenishing the helper function that the recipient's immune system can no longer provide
Data Source
Figure 1~2
Figure 3A~3B
Figure 4~5
AI summary
The invention provides methods and compositions for administration of allogeneic lymphocytes as an exogenous source of CD4+ T cell help for endogenous, tumor-reactive CD8+ T cells.